Terms: = Lymphoma AND ATRX, P46100, ZNF-HX, XNP, XH2, SHS, SFM1, RAD54, MRXHF1, MGC2094, ATR2, 546
107 results:
1. Higher mortality risk from gynaecological neoplasms and non-Hodgkin's lymphoma in patients with systemic lupus erythematosus: an observational study from the Spanish National Registry.
Moreno-Torres V; Martínez-Urbistondo M; Vázquez-Comendador J; Mateos Seirul-Lo M; Castejón R; Huerta A; Durán-Del Campo P; Tutor P; Mellor-Pita S
Lupus Sci Med; 2024 Apr; 11(1):. PubMed ID: 38631847
[TBL] [Abstract] [Full Text] [Related]
2. [Safety and efficacy of donor-derived chimeric antigen receptor T-cell therapy in patients with relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Zhuo YQ; Tu SF; Zhou X; Yang JL; Zhou LJ; Huang R; Huang YX; Li MF; Jin B; Wang B; Li SQ; Yuan ZT; Zhang LH; Liu L; Wang SB; Li YH
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):74-81. PubMed ID: 38527842
[No Abstract] [Full Text] [Related]
3. Treatment outcomes and prognostic factors of patients with lymphoblastic lymphoma in East Asia.
Kim J; Byun JM; Hong J; Koh Y; Shin DY; Kim TM; Yoon SS; Park H; Kim I
Medicine (Baltimore); 2024 Feb; 103(7):e37100. PubMed ID: 38363899
[TBL] [Abstract] [Full Text] [Related]
4. Differentiation of cancer of unknown primary and lymphoma in head and neck metastatic poorly differentiated cancer using 18 F-FDG PET/CT tumor metabolic heterogeneity index.
Xu M; Gu B; Zhang J; Xu X; Qiao Y; Hu S; Song S
Nucl Med Commun; 2024 Feb; 45(2):148-154. PubMed ID: 38095143
[TBL] [Abstract] [Full Text] [Related]
5. Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma.
Gordon MJ; Duan Z; Zhao H; Nastoupil L; Ng S; Danilov AV; Iyer S; Giordano SH
Leuk Lymphoma; 2023 Dec; 64(14):2258-2268. PubMed ID: 37706491
[TBL] [Abstract] [Full Text] [Related]
6. Impact of thyroid cancer on the cancer risk in patients with non-alcoholic fatty liver disease or dyslipidemia.
Ho J; Kim E; Lee M; Jung I; Jo YS; Lee J
Sci Rep; 2023 Jan; 13(1):1076. PubMed ID: 36658156
[TBL] [Abstract] [Full Text] [Related]
7. Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell lymphoma.
Vijenthira A; Kuruvilla J; Crump M; Jain M; Prica A
J Clin Oncol; 2023 Mar; 41(8):1577-1589. PubMed ID: 36315922
[TBL] [Abstract] [Full Text] [Related]
8. Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review.
Tesileanu CMS; Vallentgoed WR; French PJ; van den Bent MJ
Eur J Cancer; 2022 Nov; 175():214-223. PubMed ID: 36152406
[TBL] [Abstract] [Full Text] [Related]
9. The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naive ALK-positive non-small cell lung cancer from a US perspective.
Cranmer H; Kearns I; Young M; Humphries MJ; Trueman D
J Manag Care Spec Pharm; 2022 Sep; 28(9):970-979. PubMed ID: 36001099
[No Abstract] [Full Text] [Related]
10. Distribution of lymphoma subtypes in Ukraine according to the WHO 2016 classification.
Kriachok I; Stepanishyna Y; Skrypets T; Shokun N; Martynchyk A; Tytorenko I; Aleksik O; Krotevych M; Manni M; Federico M
Hematol Oncol; 2023 Feb; 41(1):196-200. PubMed ID: 35932211
[TBL] [Abstract] [Full Text] [Related]
11. Sex hormones, body mass index, and related comorbidities associated with developing Sjögren's disease: a nested case-control study.
McCoy SS; Hetzel S; VanWormer JJ; Bartels CM
Clin Rheumatol; 2022 Oct; 41(10):3065-3074. PubMed ID: 35701626
[TBL] [Abstract] [Full Text] [Related]
12. Factors associated with risk and prognosis of intensive care unit admission in patients with acute leukemia: a Danish nationwide cohort study.
Maeng CV; Christiansen CF; Liu KD; Kamper P; Christensen S; Medeiros BC; Østgård LSG
Leuk Lymphoma; 2022 Oct; 63(10):2290-2300. PubMed ID: 35583300
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic Role of Serum Albumin Level in Patients with lymphoma Undergoing Autologous Stem Cell Transplantation.
Luo C; Li Q; Li X; Wu G; Huang X; Zhang Y; Ma Y; Xie M; Sun Y; Huang Y; Huang Z; Xu S; Chen J
Ann Transplant; 2021 Oct; 26():e933365. PubMed ID: 34635633
[TBL] [Abstract] [Full Text] [Related]
14. Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma.
Fleming JL; Pugh SL; Fisher BJ; Lesser GJ; Macdonald DR; Bell EH; McElroy JP; Becker AP; Timmers CD; Aldape KD; Rogers CL; Doyle TJ; Werner-Wasik M; Bahary JP; Yu HM; D'Souza DP; Laack NN; Sneed PK; Kwok Y; Won M; Mehta MP; Chakravarti A
JCO Precis Oncol; 2021; 5():. PubMed ID: 34589661
[TBL] [Abstract] [Full Text] [Related]
15. PAX3/7-FOXO1 fusion-negative alveolar rhabdomyosarcoma in Schuurs-Hoeijmakers syndrome.
Ohkawa T; Nishimura A; Kosaki K; Aoki-Nogami Y; Tomizawa D; Kashimada K; Morio T; Kato M; Mizutani S; Takagi M
J Hum Genet; 2022 Jan; 67(1):51-54. PubMed ID: 34341476
[TBL] [Abstract] [Full Text] [Related]
16. Questioning How to Define the "Ultra-High-Risk" Subgroup of Neuroblastoma Patients.
Demir AB; Aktas S; Altun Z; Ercetin P; Aktas TC; Olgun N
Folia Biol (Praha); 2021; 67(1):1-9. PubMed ID: 34273261
[TBL] [Abstract] [Full Text] [Related]
17. Predictive Value of Dynamic Peri-Transplantation MRD Assessed By MFC Either Alone or in Combination with Other Variables for Outcomes of Patients with T-Cell Acute Lymphoblastic Leukemia.
Wang ZD; Wang YW; Xu LP; Zhang XH; Wang Y; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Wang YZ; Liu YR; Liu KY; Huang XJ; Chang YJ
Curr Med Sci; 2021 Jun; 41(3):443-453. PubMed ID: 34185250
[TBL] [Abstract] [Full Text] [Related]
18. Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.
Nakazawa A
Pathol Int; 2021 Apr; 71(4):232-244. PubMed ID: 33657257
[TBL] [Abstract] [Full Text] [Related]
19. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Borchmann P; Plütschow A; Kobe C; Greil R; Meissner J; Topp MS; Ostermann H; Dierlamm J; Mohm J; Thiemer J; Sökler M; Kerkhoff A; Ahlborn M; Halbsguth TV; Martin S; Keller U; Balabanov S; Pabst T; Vogelhuber M; Hüttmann A; Wilhelm M; Zijlstra JM; Moccia A; Kuhnert G; Bröckelmann PJ; von Tresckow B; Fuchs M; Klimm B; Rosenwald A; Eich H; Baues C; Marnitz S; Hallek M; Diehl V; Dietlein M; Engert A
Lancet Oncol; 2021 Feb; 22(2):223-234. PubMed ID: 33539742
[TBL] [Abstract] [Full Text] [Related]
20. Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis.
Strati P; Cheng PTM; Steiner RE; Alcedo Andrade PE; Feng L; Sano D; Rao VA; Singh P; Miranda R; Gunther JR; Pinnix CC; Dabaja BS; Cuglievan B; Xing K; Villa D; Skinnider B; Sehn LH; Connors JM; Nieto Y; Ahmed S; Lee HJ; Savage KJ
Br J Haematol; 2021 Feb; 192(3):560-567. PubMed ID: 33517581
[TBL] [Abstract] [Full Text] [Related]
[Next]
